These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18341668)

  • 81. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.
    Shaw PJ; Scharping CE; Brian RJ; Earl JW
    Blood; 1994 Oct; 84(7):2357-62. PubMed ID: 7919354
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
    Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
    Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
    Boland I; Vassal G; Morizet J; Terrier-Lacombe MJ; Valteau-Couanet D; Kalifa C; Hartmann O; Gouyette A
    Br J Cancer; 1999 Feb; 79(5-6):787-92. PubMed ID: 10070870
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants.
    Staatz CE; Taylor PJ; Lynch SV; Willis C; Charles BG; Tett SE
    Transplantation; 2001 Sep; 72(6):1056-61. PubMed ID: 11579300
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
    Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
    J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
    Grochow LB
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
    Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Busulphan level and early mortality in thalassaemia patients after BMT.
    Li CK; Yuen PM; Wong R; Pang CP; Lai WK; Law E; Shing MM; Chik KW; Leung TF
    Bone Marrow Transplant; 1999 Feb; 23(4):307-10. PubMed ID: 10100572
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Population pharmacokinetics of trabectedin in adolescent patients with cancer.
    Poggesi I; Valenzuela B; Ouellet D; Gonzalez M; Hillewaert V; Baruchel S; Fox E; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):707-717. PubMed ID: 31286189
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1.
    Skolnik J; Hall D; Barkauskas DA; Moorthy G; Larson TR; Fox E; Weigel BJ; Berg SL; Reid JM
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):359-365. PubMed ID: 34023919
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing.
    Hughes JH; Long-Boyle J; Keizer RJ
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):279-288. PubMed ID: 38520573
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study.
    El-Serafi A; He R; Zheng W; Benkossou F; Oerther S; Zhao Y; Mellgren K; Gustafsson B; Heilmann C; Kanerva J; Lotfi K; Toporski J; Sundin M; Höglund M; Mattsson J; El-Serafi I; Hassan M
    Bone Marrow Transplant; 2021 Apr; 56(4):807-817. PubMed ID: 33087877
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
    Lawson R; Staatz CE; Fraser CJ; Ramachandran S; Teague L; Mitchell R; O'Brien T; Hennig S
    CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):1002-1017. PubMed ID: 35611997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.